Ownership history in BENDER ROBERT & ASSOCIATES · 9 quarters on record
This page tracks every 13F SEC filing in which BENDER ROBERT & ASSOCIATES reported a position in BIOCRYST PHARMACEUTICALS INC (BCRX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | UNCHANGED | 23,710 | — | 0% | 0.04% | $180K | $7.59 |
| 2025 Q2 | UNCHANGED | 23,710 | — | 0% | 0.05% | $212K | $8.96 |
| 2024 Q4 | REDUCED | 23,710 | -32,890 | -58.1% | 0.04% | $178K | $7.52 |
| 2023 Q4 | UNCHANGED | 56,600 | — | 0% | 0.09% | $339K | $5.99 |
| 2023 Q3 | REDUCED | 56,600 | -12,000 | -17.5% | 0.12% | $401K | $7.08 |
| 2023 Q2 | UNCHANGED | 68,600 | — | 0% | 0.13% | $483K | $7.04 |
| 2023 Q1 | UNCHANGED | 68,600 | — | 0% | 0.18% | $572K | $8.34 |
| 2022 Q3 | UNCHANGED | 68,600 | — | 0% | 0.33% | $864K | $12.60 |
| 2022 Q2 | INITIATED | 68,600 | — | — | 0.28% | $726K | $10.58 |
As of 2025 Q4 — sorted by position size